Sun Pharmaceuticals traded at 1,941.10 this Friday July 24th, decreasing 12.90 or 0.66 percent since the previous trading session. Looking back, over the last four weeks, Sun Pharmaceuticals lost 4.20 percent. Over the last 12 months, its price rose by 14.25 percent. Looking ahead, we forecast Sun Pharmaceuticals to be priced at 1,897.43 by the end of this quarter and at 1,772.21 in one year, according to Trading Economics global macro models projections and analysts expectations.
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.